Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

SGTX : 22.47 (-2.56%)
ATRS : 5.59 (unch)
VCEL : 59.11 (+4.23%)
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme...

ATRS : 5.59 (unch)
HALO : 49.00 (+7.22%)
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS

Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders...

ATRS : 5.59 (unch)
HALO : 49.00 (+7.22%)
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme...

ATRS : 5.59 (unch)
HALO : 49.00 (+7.22%)
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
GSK : 33.96 (+0.77%)
SRRA : 54.99 (+0.04%)
ATRS : 5.59 (unch)
CLVS : 0.0812 (-5.58%)
TPTX : 76.01 (+0.69%)
Delta, Fastenal rise; JPMorgan Chase, NanoString fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:

ASH : 79.05 (+1.82%)
FAST : 83.08 (+0.87%)
ATRS : 5.59 (unch)
DAL : 63.34 (unch)
JPM : 248.55 (+1.55%)
Why Antares Pharma Stock Is Bolting Higher Today

The drug delivery specialist has reportedly agreed to a merger with Halozyme.

ATRS : 5.59 (unch)
HALO : 49.00 (+7.22%)
ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma...

ATRS : 5.59 (unch)
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share ...

ATRS : 5.59 (unch)
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced...

ATRS : 5.59 (unch)

Barchart Exclusives

1 Cathie Wood Stock to Buy Now and Hold for Long-Term Upside
This Cathie Wood stock just received an upgrade from an analyst who recommends it for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar